Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.52 |
| ▸ | XIAP | P98170 | 9/20 | 0.44 |
| ▸ | BIRC3 | Q13489 | 9/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067306 | 1.00 | TNF (0.52) | TNFXIAPBIRC3CYP3A4BIRC2 | |
| SCHEMBL24067407 | 0.92 | TNF (0.44) | TNFXIAPBIRC3CYP3A4BIRC2 | |
| SCHEMBL24067321 | 0.92 | TNF (0.44) | TNFXIAPBIRC3CYP3A4BIRC2 | |
| SCHEMBL22450736 | 0.88 | TNF (0.53) | TNFXIAPBIRC3CYP3A4BIRC2 | |
| SCHEMBL24182198 | 0.88 | TNF (0.53) | TNFXIAPBIRC3CYP3A4BIRC2 | |
| SCHEMBL22450711 | 0.88 | TNF (0.53) | TNFXIAPBIRC3CYP3A4BIRC2 | |
| SCHEMBL22450740 | 0.87 | TNF (0.52) | TNFXIAPBIRC3CYP3A4BIRC2 | |
| SCHEMBL22450669 | 0.87 | TNF (0.52) | TNFXIAPBIRC3CYP3A4BIRC2 | |
| SCHEMBL24067368 | 0.87 | TNF (0.52) | TNFXIAPBIRC3CYP3A4BIRC2 | |
| SCHEMBL22450729 | 0.87 | TNF (0.52) | TNFXIAPBIRC3CYP3A4BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | TNF 1106/4885XIAP 2/4885BIRC3 4/4885 |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | BIRC7, BIRC5, BIRC2 | TNF 1538/4885XIAP 6/4885BIRC3 4/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | TNF 1538/4885XIAP 6/4885BIRC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.